Article Information
History
- December 30, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Yinong Young-Xu, ScD, MA, MS1,2,*,
- Caroline Korves, ScD1,
- Gabrielle Zwain, BA1,
- Sacha Satram, PhD3,
- Myriam Drysdale, PhD, PharmD, MPH4,
- Carolina Reyes, PhD3,
- Mindy M. Cheng, PhD, MS3,
- Lauren Epstein, MD5,6,
- Vincent C. Marconi, MD5,6,7 and
- Adit Ginde, MD8
- 1White River Junction Veterans Affairs Medical Center, White River Junction, VT
- 2Geisel School of Medicine at Dartmouth, Hanover, NH
- 3Vir Biotechnology, San Francisco, California, USA
- 4GSK, Brentford, Middlesex, UK
- 5Atlanta Veterans Affairs Medical Center, Decatur, GA
- 6Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA
- 7Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA
- 8Department of Emergency Medicine, University of Colorado School of Medicine, Aurora. CO
- ↵*Corresponding author:
Yinong Young-Xu ScD, MA, MS; White River Junction Veterans Affairs Medical Center; White River Junction, VT 05009; Yinong.Young-Xu{at}VA.gov;
Posted December 30, 2022.
Effectiveness of Sotrovimab in Preventing COVID-19-related Hospitalizations or Deaths Among U.S. Veterans
